Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Studied for simultaneous GLP-1, GIP and glucagon receptor activation
All insurance plans, including Medicare and Medicaid, have a formulary, which is a list of covered drugs in a tier system
In contrast, semaglutide, liraglutide, and dulaglutide undergo proteolytic degradation with minimal renal clearance, making them suitable options for patients with renal impairment, though caution is still advised
Not available to Medicare or Medi-Cal beneficiaries
The ECL3 of the GLP-1R:TT-OAD complex was removed for clarity
Retatrutide has shown promising diabetes management results in clinical trials, with significant improvements in blood sugar control and insulin sensitivity
US$ 23.77
US$ 20.36
US$ 26.23
US$ 22.18
US$ 29.63
